GR3031479T3 - Drug system. - Google Patents

Drug system.

Info

Publication number
GR3031479T3
GR3031479T3 GR990402571T GR990402571T GR3031479T3 GR 3031479 T3 GR3031479 T3 GR 3031479T3 GR 990402571 T GR990402571 T GR 990402571T GR 990402571 T GR990402571 T GR 990402571T GR 3031479 T3 GR3031479 T3 GR 3031479T3
Authority
GR
Greece
Prior art keywords
polysaccharide
drug
matrix
drug system
natural macromolecule
Prior art date
Application number
GR990402571T
Other languages
English (en)
Inventor
Margaret Joan Taylor
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montfort filed Critical Univ Montfort
Publication of GR3031479T3 publication Critical patent/GR3031479T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
GR990402571T 1992-01-10 1999-10-08 Drug system. GR3031479T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200638A GB9200638D0 (en) 1992-01-10 1992-01-10 Drug system
PCT/GB1993/000034 WO1993013803A1 (en) 1992-01-10 1993-01-08 Drug system

Publications (1)

Publication Number Publication Date
GR3031479T3 true GR3031479T3 (en) 2000-01-31

Family

ID=10708507

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402571T GR3031479T3 (en) 1992-01-10 1999-10-08 Drug system.

Country Status (11)

Country Link
US (2) US5830506A (el)
EP (1) EP0626862B1 (el)
JP (1) JP4025363B2 (el)
AT (1) ATE183927T1 (el)
AU (1) AU3263093A (el)
DE (1) DE69326234T2 (el)
DK (1) DK0626862T3 (el)
ES (1) ES2135458T3 (el)
GB (1) GB9200638D0 (el)
GR (1) GR3031479T3 (el)
WO (1) WO1993013803A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
AU6931500A (en) * 1999-08-27 2001-03-26 M-Biotech, Inc. Glucose biosensor
EP1309845A4 (en) * 2000-04-22 2005-10-12 Biotech Inc M HYDROGEL BIOSENSOR AND BIOSENSORIES-BASED HEALTH ALARM SYSTEM
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
AU2002331618B2 (en) 2001-08-17 2007-11-01 University Of Pittsburgh Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
US20060194775A1 (en) * 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
EP1610798A4 (en) * 2003-02-20 2007-08-08 Univ Pittsburgh ESTRADIOL METABOLITES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
MX2011007930A (es) 2009-01-28 2011-09-06 Smartcells Inc Conjugados de insulina cristalina.
CA2932926C (en) 2009-01-28 2018-12-18 Smartcells, Inc. Conjugate based systems for controlled drug delivery
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
GB201314640D0 (en) 2013-08-15 2013-10-02 Univ Montfort Matrix gel
AR097893A1 (es) 2013-10-04 2016-04-20 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa
EP3600381A4 (en) 2017-03-23 2021-06-16 Merck Sharp & Dohme Corp. GLUCOSE-ACTIVE INSULIN WITH A THREE-VALUE SUGAR CLUSTER FOR THE TREATMENT OF DIABETES
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
JP3296817B2 (ja) * 1991-04-02 2002-07-02 バイオテック・オーストラリア・ピーティーワイ・リミテッド 微粒子に適した経口配布系
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii

Also Published As

Publication number Publication date
ES2135458T3 (es) 1999-11-01
AU3263093A (en) 1993-08-03
EP0626862B1 (en) 1999-09-01
US20020168409A1 (en) 2002-11-14
DK0626862T3 (da) 1999-12-13
DE69326234T2 (de) 1999-12-30
US7063863B2 (en) 2006-06-20
WO1993013803A1 (en) 1993-07-22
DE69326234D1 (de) 1999-10-07
JPH07507268A (ja) 1995-08-10
GB9200638D0 (en) 1992-03-11
EP0626862A1 (en) 1994-12-07
ATE183927T1 (de) 1999-09-15
US5830506A (en) 1998-11-03
JP4025363B2 (ja) 2007-12-19

Similar Documents

Publication Publication Date Title
GR3031479T3 (en) Drug system.
Draget et al. Alginate based new materials
US4189370A (en) Process for obtaining gels of N-methylol-acrylamide copolymers and application of said gels for the stepped gradient separation of seric lipoproteins
CN108676178B (zh) 改性多糖水凝胶的制备方法及制备的改性多糖水凝胶
Rousseau et al. Entrapment and release of sodium polystyrene sulfonate (SPS) from calcium alginate gel beads
US5902607A (en) Reversible cross-linked gel
GB1463301A (en) Polymer properties
ES8206984A1 (es) Procedimiento de separacion de mezclas biologicas
AU3877200A (en) Hydrogel-forming system with hydrophobic and hydrophilic components
GB1283857A (en) Size for glass fibres
YU46797B (sh) Postupak za dobijanje ojačanog poliuretanskog polimera
CA2112450A1 (en) Cross-linked linear polysaccharide polymers as gels for electrophoresis
DE3167132D1 (en) Gel based on water-soluble poly(meth)acrylic acid derivatives, process for its preparation and its use
EP0401044A3 (en) Absorbent polymers and their production
NO940112D0 (no) Fremgangsmaate for fremstilling av en dispersjon og for fremstilling av polymerpartikler
NO131417B (el)
Yook et al. Application of heat/moisture-treated rices for Sikhe preparation
EA199900918A2 (ru) Способ получения монодисперсных гелеобразных катионитов
De Moor et al. Long-term structural changes in pH-sensitive hydrogels
Attri et al. A systematic review on grafting techniques and their applications with reference to natural gums and mucilage
Shiino et al. Controlled release of insulin from boronic acid gel under physiological conditions
US5215752A (en) Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
CN112142932B (zh) 一种具有调控药物相反释放行为的pH响应UV交联壳聚糖水凝胶的制备方法
Budtova et al. Polyelectrolyte hydrogel swelling in a concentrated polymer solution
EP0333105B1 (en) Pharmaceutical tablets and capsule granulates of scleroglucan and active substance